Roche’s Polivy Among Seven New Drugs On Track For EU-Wide Approval
Conditional Approval In Store For The Lymphoma Treatment
Seven drugs, including two orphans and two generics, are on track to receive pan-EU approval.
You may also be interested in...
Is the benefit-risk profile of tafasitamab good enough for it to be recommended for EU-wide marketing approval? Codevelopers Incyte and MorphoSys may find out this week.
Rigel Pharmaceuticals and Jazz Pharmaceuticals are among the companies that could find out this week whether their new drug applications at the European Medicines Agency are likely to be approved for marketing across the EU. The EMA's key scientific committee, the CHMP, will also consider applications from Roche and Novartis.
Novartis is likely to hear this week whether siponomid and osilodrostat will be recommended for marketing across the EU.